Accelerate Diagnostics, Inc. (AXDX) News
Filter AXDX News Items
AXDX News Results
|Loading, please wait...|
Latest AXDX News From Around the Web
Below are the latest news stories about ACCELERATE DIAGNOSTICS INC that investors may wish to consider to help them evaluate AXDX as an investment opportunity.
Q2 2023 Accelerate Diagnostics Inc Earnings Call
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -57.33% and 26.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time to review 2023 second quarter results.
Accelerate Diagnostics, Inc., (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on July 11, 2023. The Company's common stock will begin trading on a post-split basis at the market open on July 12, 2023, under the Company's existing trading symbol "AXDX". The reverse
Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
Accelerate Diagnostics, Inc., (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement. Through a series of transactions, the company has simplified its capital structure, extended-out its debt maturity 3.5 years and secured $24 million of new funding, providing opportunities for future growth and innovation.
Individual investors invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) up 45% last week, insiders too were rewarded
Key Insights The considerable ownership by individual investors in Accelerate Diagnostics indicates that they...
Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.